Cytotoxic Effects of Plant Secondary Metabolites and Naturally Occurring Bioactive Peptides on Breast Cancer Model Systems: Molecular Mechanisms

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2024 Nov 27

PMID 39598664

Authors

Diana Zasheva

Petko Mladenov

Silvina Zapryanova

Zlatina Gospodinova

Mariyana Georgieva

Irina Alexandar

Valentin Velinov

Dimitar Djilianov

Daniela Moyankova

Lyudmila Simova-Stoilova

Affiliations

Soon will be listed here.

Abstract

Breast cancer is the second leading cause of death among women, and the number of mortal cases in diagnosed patients is constantly increasing. The search for new plant compounds with antitumor effects is very important because of the side effects of conventional therapy and the development of drug resistance in cancer cells. The use of plant substances in medicine has been well known for centuries, but the exact mechanism of their action is far from being elucidated. The molecular mechanisms of cytotoxicity exerted by secondary metabolites and bioactive peptides of plant origin on breast cancer cell lines are the subject of this review.

Citing Articles

Antin-diabetic cognitive dysfunction effects and underpinning mechanisms of phytogenic bioactive peptides: a review.

Liu X, Mao S, Yuan Y, Wang Z, Tian Y, Tao L Front Nutr. 2025; 11:1517087.

PMID: 39867560 PMC: 11758632. DOI: 10.3389/fnut.2024.1517087.

References

Moy L, Billings P . A proteolytic activity in a human breast cancer cell line which is inhibited by the anticarcinogenic Bowman-Birk protease inhibitor. Cancer Lett. 1994; 85(2):205-10. DOI: 10.1016/0304-3835(94)90276-3. View

Lake B . Coumarin metabolism, toxicity and carcinogenicity: relevance for human risk assessment. Food Chem Toxicol. 1999; 37(4):423-53. DOI: 10.1016/s0278-6915(99)00010-1. View

Ono M, Kuwano M . Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res. 2006; 12(24):7242-51. DOI: 10.1158/1078-0432.CCR-06-0646. View

Nurse P . Nobel Lecture. Cyclin dependent kinases and cell cycle control. Biosci Rep. 2003; 22(5-6):487-99. DOI: 10.1023/a:1022017701871. View

Ryan J, Heckler C, Ling M, Katz A, Williams J, Pentland A . Curcumin for radiation dermatitis: a randomized, double-blind, placebo-controlled clinical trial of thirty breast cancer patients. Radiat Res. 2013; 180(1):34-43. PMC: 3998827. DOI: 10.1667/RR3255.1. View

Hsieh C, Wu C, Peng S, Chang C . Seed-derived peptide lunasin suppressed breast cancer cell growth by regulating inflammatory mediators, aromatase, and estrogen receptors. Food Nutr Res. 2023; 67. PMC: 9899045. DOI: 10.29219/fnr.v67.8991. View

Aggarwal B, Shishodia S, Takada Y, Banerjee S, Newman R, Bueso-Ramos C . Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res. 2005; 11(20):7490-8. DOI: 10.1158/1078-0432.CCR-05-1192. View

Zhang L, Wan X, Donahue J, Ware J, Kennedy A . Effects of the Bowman-Birk inhibitor on clonogenic survival and cisplatin- or radiation-induced cytotoxicity in human breast, cervical, and head and neck cancer cells. Nutr Cancer. 1999; 33(2):165-73. DOI: 10.1207/S15327914NC330208. View

Kim E, Kim H, Koh J, Kim M, Kim K, Lee J . Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2010; 126(1):93-9. DOI: 10.1007/s10549-010-1315-z. View

10.

Greenshields A, Doucette C, Sutton K, Madera L, Annan H, Yaffe P . Piperine inhibits the growth and motility of triple-negative breast cancer cells. Cancer Lett. 2014; 357(1):129-140. DOI: 10.1016/j.canlet.2014.11.017. View

11.

Mazumder K, Biswas B, Raja I, Fukase K . A Review of Cytotoxic Plants of the Indian Subcontinent and a Broad-Spectrum Analysis of Their Bioactive Compounds. Molecules. 2020; 25(8). PMC: 7221707. DOI: 10.3390/molecules25081904. View

12.

Huang Y, Peng H, Zeng A, Song L . The role of peptides in reversing chemoresistance of breast cancer: current facts and future prospects. Front Pharmacol. 2023; 14:1188477. PMC: 10239817. DOI: 10.3389/fphar.2023.1188477. View

13.

Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B . The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Adv Pharm Bull. 2017; 7(3):339-348. PMC: 5651054. DOI: 10.15171/apb.2017.041. View

14.

Bjornstrom L, Sjoberg M . Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol. 2005; 19(4):833-42. DOI: 10.1210/me.2004-0486. View

15.

Stierle A, Strobel G, Stierle D . Taxol and taxane production by Taxomyces andreanae, an endophytic fungus of Pacific yew. Science. 1993; 260(5105):214-6. DOI: 10.1126/science.8097061. View

16.

Chen Y, Huang S, Lin-Shiau S, Lin J . Bowman-Birk inhibitor abates proteasome function and suppresses the proliferation of MCF7 breast cancer cells through accumulation of MAP kinase phosphatase-1. Carcinogenesis. 2005; 26(7):1296-306. DOI: 10.1093/carcin/bgi062. View

17.

Cui N, Lin D, Shen Y, Shi J, Wang B, Zhao M . Triphenylethylene-Coumarin Hybrid TCH-5c Suppresses Tumorigenic Progression in Breast Cancer Mainly Through the Inhibition of Angiogenesis. Anticancer Agents Med Chem. 2019; 19(10):1253-1261. DOI: 10.2174/1871520619666190404155230. View

18.

Kaufman-Szymczyk A, Kaczmarek W, Fabianowska-Majewska K, Lubecka-Gajewska K . Lunasin and Its Epigenetic Impact in Cancer Chemoprevention. Int J Mol Sci. 2023; 24(11). PMC: 10253126. DOI: 10.3390/ijms24119187. View

19.

Clusan L, Ferriere F, Flouriot G, Pakdel F . A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer. Int J Mol Sci. 2023; 24(7). PMC: 10095386. DOI: 10.3390/ijms24076834. View

20.

Petrova L, Gergov N, Stoup M, Zapryanova S, Van Damme E, Lebegue N . Jacalin-Curcumin Complex Sensitizes the Breast Cancer MDA-MB-231 Cell Line. Int J Mol Sci. 2023; 24(24). PMC: 10743388. DOI: 10.3390/ijms242417399. View